Singh Amrit Pal, Singh Randhir, Krishan Pawan
1Department of Pharmaceutical Sciences,Guru Nanak Dev University,Amritsar 143005,India.
2Department of Pharmacology,Maharishi Markandeshwar College of Pharmacy,Maharishi Markandeshwar University,Mullana,Ambala 133207,India.
Cardiol Young. 2015 Apr;25(4):725-30. doi: 10.1017/S104795111400081X. Epub 2014 Jun 6.
Fibrates are peroxisome proliferator-activated receptor-α agonists and are clinically used for treatment of dyslipidemia and hypertriglyceridemia. Fenofibrate is reported as a cardioprotective agent in various models of cardiac dysfunction; however, limited literature is available regarding the role of gemfibrozil as a possible cardioprotective agent, especially in a non-obese model of cardiac remodelling. The present study investigated the role of gemfibrozil against partial abdominal aortic constriction-induced cardiac hypertrophy in rats. Cardiac hypertrophy was induced by partial abdominal aortic constriction in rats and they survived for 4 weeks. The cardiac hypertrophy was assessed by measuring left ventricular weight to body weight ratio, left ventricular wall thickness, and protein and collagen content. The oxidative stress in the cardiac tissues was assessed by measuring thiobarbituric acid-reactive substances, superoxide anion generation, and reduced glutathione level. The haematoxylin-eosin and picrosirius red staining was used to observe cardiomyocyte diameter and collagen deposition, respectively. Moreover, serum levels of cholesterol, high-density lipoproteins, triglycerides, and glucose were also measured. Gemfibrozil (30 mg/kg, p.o.) was administered since the first day of partial abdominal aortic constriction and continued for 4 weeks. The partial abdominal aortic constriction-induced cardiac oxidative stress and hypertrophy are indicated by significant change in various parameters used in the present study that were ameliorated with gemfibrozil treatment in rats. No significant change in serum parameters was observed between various groups used in the present study. It is concluded that gemfibrozil ameliorates partial abdominal aortic constriction-induced cardiac oxidative stress and hypertrophy and in rats.
纤维酸类药物是过氧化物酶体增殖物激活受体-α激动剂，临床上用于治疗血脂异常和高甘油三酯血症。非诺贝特在各种心脏功能障碍模型中被报道为一种心脏保护剂；然而，关于吉非贝齐作为一种可能的心脏保护剂的作用，尤其是在非肥胖心脏重塑模型中的文献有限。本研究调查了吉非贝齐对大鼠部分腹主动脉缩窄诱导的心脏肥大的作用。通过部分腹主动脉缩窄诱导大鼠心脏肥大，并使其存活4周。通过测量左心室重量与体重比、左心室壁厚度以及蛋白质和胶原蛋白含量来评估心脏肥大。通过测量硫代巴比妥酸反应性物质、超氧阴离子生成量和还原型谷胱甘肽水平来评估心脏组织中的氧化应激。苏木精-伊红染色和天狼星红染色分别用于观察心肌细胞直径和胶原蛋白沉积。此外，还测量了血清中的胆固醇、高密度脂蛋白、甘油三酯和葡萄糖水平。自部分腹主动脉缩窄第一天起给予吉非贝齐（30mg/kg，口服），持续4周。本研究中使用的各种参数的显著变化表明部分腹主动脉缩窄诱导的心脏氧化应激和肥大，而吉非贝齐治疗可改善大鼠的这些变化。本研究中使用的各组之间血清参数未观察到显著变化。得出结论，吉非贝齐可改善大鼠部分腹主动脉缩窄诱导的心脏氧化应激和肥大。
